News

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

August 15, 2023

Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

August 10, 2023

Kurin Launches Kurin Jet, Redefining the Blood Culture Contamination Device Market

July 12, 2023

USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

May 3, 2023

Kurin Receives 510k from the FDA with Indication to Reduce Blood Culture Contaminations

May 2, 2023

Kurin Commends the CDC for Their Recent Publication on Blood Culture Contamination

March 14, 2023

ENA Welcomes Kurin to 2023 Corporate Engagement Council

March 8, 2023

Kurin Announces Kurin Jet, A Quantum Leap Forward in Devices Designed to Address Blood Culture Contamination

February 15, 2023

Kurin, Inc. Reports Record Revenue for 2022

January 26, 2023

Kurin, Inc. Announces Successful FDA Audit

September 28, 2022

Kurin, Inc. Provides Update on Litigation Activity

September 15, 2022

Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle

September 7, 2022

Kurin, Inc. Statement Regarding Patent Litigation

August 3, 2022

U.S. District Court Enters Judgment of No Infringement of Patent Asserted Against Kurin Inc. by Magnolia Medical Technologies, Inc.

June 16, 2022

Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

February 23, 2022

Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures

January 18, 2022

Kurin, Inc. Reports Record Sales for Q4 and Total 2021 Revenues

January 11, 2022

Kurin, Inc. Reports Record Q3 Sales

October 18, 2021

Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™

October 5, 2021

Kurin, Inc. Reports Record Sales Month

August 10, 2021
1 2 3

ML-021 Rev A